Talphera Inc. (TLPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Talphera Inc. (TLPH) has a cash flow conversion efficiency ratio of -0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($19.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Talphera Inc. - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Talphera Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Talphera Inc. carry for a breakdown of total debt and financial obligations.
Talphera Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talphera Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
0.015x |
|
Mondi PLC
LSE:MNDI
|
0.036x |
|
Nusa Konstruksi Enjiniring Tbk
JK:DGIK
|
-0.053x |
|
GFG Resources Inc
V:GFG
|
-0.012x |
|
Lider Faktoring AS
IS:LIDFA
|
-0.140x |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
-21.169x |
|
Canlan Ice Sports Corp.
TO:ICE
|
0.085x |
|
Panorama Sentrawisata Tbk
JK:PANR
|
0.015x |
Annual Cash Flow Conversion Efficiency for Talphera Inc. (2008–2024)
The table below shows the annual cash flow conversion efficiency of Talphera Inc. from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Talphera Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.00 Million | $-12.68 Million | -1.585x | -27.82% |
| 2023-12-31 | $14.11 Million | $-17.49 Million | -1.240x | +4.51% |
| 2022-12-31 | $21.81 Million | $-28.33 Million | -1.299x | -255.38% |
| 2021-12-31 | $-35.89 Million | $-30.00 Million | 0.836x | +21.02% |
| 2020-12-31 | $-55.75 Million | $-38.51 Million | 0.691x | -44.11% |
| 2019-12-31 | $-41.42 Million | $-51.18 Million | 1.236x | +118.08% |
| 2018-12-31 | $4.25 Million | $-29.07 Million | -6.836x | -938.53% |
| 2017-12-31 | $-36.51 Million | $-29.77 Million | 0.815x | -85.20% |
| 2016-12-31 | $-5.34 Million | $-29.39 Million | 5.508x | +1014.04% |
| 2015-12-31 | $33.11 Million | $-19.95 Million | -0.603x | +18.41% |
| 2014-12-31 | $46.66 Million | $-34.46 Million | -0.739x | -10994.20% |
| 2013-12-31 | $73.16 Million | $-487.00K | -0.007x | +99.08% |
| 2012-12-31 | $33.85 Million | $-24.58 Million | -0.726x | +17.01% |
| 2011-12-31 | $17.47 Million | $-15.29 Million | -0.875x | -571.70% |
| 2010-12-31 | $-65.89 Million | $-12.22 Million | 0.186x | -49.37% |
| 2009-12-31 | $-52.99 Million | $-19.42 Million | 0.366x | -35.38% |
| 2008-12-31 | $-33.34 Million | $-18.90 Million | 0.567x | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more